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BACKGROUND: Information regarding the possible influence of immunosuppressive drugs on male sexual function and reproductive
outcomes is scarce. Men diagnosed with immune-mediated diseases and a wish to become a father represent an important neglected
population since they lack vital information to make balanced decisions about their treatment.
OBJECTIVE AND RATIONALE: The aim of this research was to systematically review the literature for the influence of paternal
immunosuppressive drug use on many aspects of male sexual health, such as sexual function, fertility, pregnancy outcomes and offspring
health outcomes.
SEARCH METHODS: A systematic literature search was performed in the bibliographic databases: Embase (via Elsevier embase.com),
MEDLINE ALL via Ovid, Cochrane Central Register of Trials (via Wiley) and Web of Science Core Collection. Additionally, Google
Scholar and the Clinical trial registries of Europe and the USA were searched. The databases were searched from inception until
31 August 2019. The searches combined keywords regarding male sexual function and fertility, pregnancy outcomes and offspring health
with a list of immunosuppressive drugs. Studies were included if they were published in English and if they included original data on male
human exposure to immunosuppressive drugs. A meta-analysis was not possible to perform due to the heterogeneity of the data.
OUTCOMES: A total of 5867 references were identified, amongst which we identified 161 articles fulfilling the eligibility criteria. Amongst
these articles, 50 included pregnancy and offspring outcomes and 130 included sexual health outcomes. Except for large Scandinavian
cohorts, most of the identified articles included a small number of participants. While a clear negative effect on sperm quality was evident
for sulfasalazine and cyclophosphamide, a dubious effect was identified for colchicine, methotrexate and sirolimus. In three articles,
exposure to tumour necrosis factor-a inhibitors in patients diagnosed with ankylosing spondylitis resulted in improved sperm quality. The
information regarding pregnancy and offspring outcomes was scant but no large negative effect associated with paternal immunosuppressive
drug exposure was reported.
WIDER IMPLICATIONS: Evidence regarding the safety of immunosuppressive drugs in men with a wish to become a father is inconclu-
sive. The lack of standardisation on how to evaluate and report male sexual function, fertility and reproduction as study outcomes in men
exposed to immunosuppressive drugs is an important contributor to this result. Future research on this topic is needed and should be
preferably done using standardised methods.
Key words: immunosuppressive agents / semen analysis / male infertility / sexual health / sexual dysfunction / hypogonadism / teratoge-
nicity / pregnancy / paternal exposure / gonadal steroid hormones
Introduction
Men with immune-mediated diseases (IMDs) and a wish to become a
father represent an important neglected population. The question on
how they should be treated to improve (or at least not impair) their
chances of achieving a successful pregnancy and a healthy offspring
remains a challenge for physicians and researchers all around the world.
Based on data from Denmark, the Netherlands and Norway, it is
estimated that 5.6–7.6% of fathers could be exposed to non-steroidal
anti-inflammatory drugs (NSAIDs) or anti-rheumatic drugs during the
pre-conceptional period (3 or 6 months before pregnancy) (Schirm
et al., 2004; Crijns et al., 2012; Engeland et al., 2013). Many factors are
contributing to a substantial number of men with a wish to become a
father being exposed to immunosuppressive drugs; some IMDs can af-
fect men at a young age (i.e. juvenile idiopathic arthritis), then the
prevalence of other IMDs increases during the peak of the male repro-
ductive lifespan (i.e. rheumatoid arthritis (RA) or inflammatory bowel
disease (IBD)), and furthermore in many parts of the world, men are
becoming fathers at an older age (Khandwala et al., 2017).































































































It is known that immunosuppressive drugs can affect male sexual
health and reproduction via multiple mechanisms: by altering repro-
ductive hormone secretion and/or action, by disrupting spermatogen-
esis or sperm motility and by causing sexual dysfunction (Sasaki et al.,
2011).
Furthermore, many of the available immunosuppressive drugs, such
as methotrexate or sulfasalazine, were approved by the Food and
Drug Administration (FDA) and/or the European Medicines Agency
(EMA) before it was required to perform mandatory evaluations of
male reproductive toxicity (FDA, 2015; EMA, 2017)
On the contrary, to get approval, new drugs are facing more strict
protocols. Testicular toxicity is first evaluated in animal studies. When
evidence suggests adverse events on the male reproductive system,
complex trials in humans should follow. Importantly, in animal studies,
the FDA considers histopathological evaluation to be an appropriate
endpoint. In the case of human studies, semen analyses at baseline, at
one spermatogenic cycle after exposure and at 13 weeks after drug
discontinuation) become the most important marker of fertility. For
further reassurance of testicular safety, the FDA recommends con-
ducting randomised, double-blind, placebo-controlled, parallel-arm tri-
als including 200 men in a 1:1 ratio (drug:placebo) (FDA, 2015).
For men of reproductive age, the decision on which immunosup-
pressive drug to prescribe is not straightforward. Information regarding
the possible effects on male sexual health and reproduction is still lack-
ing for most of the commonly used immunosuppressive drugs.
The objective of our study is to provide this information in the form
of a ‘state of the art’ systematic review. Our goal is to review the
available information about the influence of paternal immunosuppres-
sive drug exposure on many aspects of male sexual and reproductive
health, such as sexual function, reproductive hormones, fertility, preg-
nancy and offspring outcomes.
Methods
Protocol and registration
The protocol for this systematic review was registered with the
International Prospective Register of Systematic Reviews (Registration
no. CRD42018096898, https://www.crd.york.ac.uk/prospero/display_
record.php?RecordID¼96898) and undertaken according to the
Preferred Reporting Items for Systematic Reviews and Meta-analyses
protocols (PRISMA-P) guidelines (Moher et al., 2015).
Eligibility criteria
The literature search was limited to the English language and human
subjects. Case–control studies, cohort studies, cross-sectional studies,
case reports and case series were included. In vitro studies using hu-
man material were also included. Conference abstracts published after
April 2016 were included. Publications without original data, such as
reviews, were excluded. Publications concerning the use of immuno-
suppressive drugs for the treatment of any form of cancer were
excluded.
The outcome data should include at least one of the following out-
comes: sexual function, reproductive hormones, fertility, pregnancy
outcomes or offspring outcomes. For pregnancy outcomes,
publications were included if paternal exposure of immunosuppressive
drugs took place in the 6 months before or around the time of con-
ception, and in case of studies reporting sexual function or fertility
parameters (i.e. semen analysis, sexual dysfunction and testosterone
levels), publications were included if male exposure of immunosup-
pressive drugs was taken into consideration. For both categories, no
restrictions were made regarding the comparison groups.
Information sources and search terms
A search strategy was developed by an experienced medical librarian
(W.B.) using a structured methodology (Bramer et al., 2018a,b). The
searches combined keywords regarding male sexual function and fertil-
ity, pregnancy outcomes and offspring health with a list of immunosup-
pressive drugs collected by experts in the fields of Rheumatology,
Gastroenterology, Dermatology and Nephrology. Our full electronic
search strategy is provided in Supplementary Table S1.
Subsequently, a systematic literature search was performed in the
bibliographic databases: Embase (via Elsevier embase.com), MEDLINE
ALL (via Ovid), Cochrane Central Register of Trials (via Wiley) and
Web of Science Core Collection. Additionally, Google Scholar and the
Clinical trial registries of Europe and the USA were searched. We also
included references from the primary search publications, in case these
were missed in our search and when relevant data were missing, we
contacted authors for further information. These databases were
searched from inception until 31 August 2019.
Study selection and data extraction
All articles were imported into EndNote X9. After removal of dupli-
cates with the method described by Bramer et al. (2016), two
reviewers (L.F.P.-G. and B.t.W.) independently screened titles,
abstracts and full-text of the records for eligibility. Disagreements were
resolved by consensus with the help of a third reviewer (R.J.E.M.D.).
Two reviewers (L.F.P.-G. and B.t.W.) extracted relevant information
for each studied outcome from the included articles.
Risk of bias in individual studies
The methodological quality of the studies was assessed with the
Newcastle–Ottawa Scale (NOS), developed for case–control and co-
hort studies (Wells et al., 2013). In the case of cross-sectional studies,
an adapted scale was used (Modesti et al., 2016). Using these meth-
ods, points were awarded to each publication, related to the selection
of the study group, the comparability of the study groups and the as-
certainment of the outcomes. The score ranges from 0 to 9, with
scores >5 representing good-quality studies. The results are presented
in Tables I and II. Case reports were not graded. Quality assessment
was done by L.F.P-G. for the sexual function, reproductive hormones
and fertility data, and by B.t.W. and S.V. for pregnancy and child out-
come data.
Regarding pregnancy and child outcomes data, the following ‘rules’
were applied. Ascertainment exposure/outcome was graded ‘1’
(structured questionnaire equals structured interview). The question
‘outcome not present at the start’ was always graded ‘0’. Follow-up
length was considered long enough for congenital anomalies if at least
1-year follow-up was reported. For long-term outcomes, the follow-
up needed to last until children were 18 years of age. In cases where




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































publications included maternal and paternal outcomes, the score was
based only on the paternal outcomes.
Synthesis of results
Sexual health outcomes were classified into two categories: (i) sexual
function, reproductive hormones and fertility (e.g. sexual dysfunction,
testosterone and sperm quality) and (ii) pregnancy and offspring out-
comes (e.g. live births, spontaneous abortions, premature birth, low
birth weight and congenital anomalies).
Additional analysis
A meta-analysis was not possible to perform due to the heterogenicity
of the data.
Results
Study selection and characteristics
A total of 5867 references were identified (2366 from Embase, 2023
from Medline, 1315 from Web of Science and 163 from Cochrane
central) and imported into EndNote X9. After removing 1663 dupli-
cates, 4204 articles were eligible for title and abstract screening.
During this phase, 3850 articles were excluded and 354 articles were
eligible for full-text reading. Then 193 articles were excluded after full-
text reading (see flowchart in Fig. 1). Additionally 15 articles that ful-
filled the inclusion criteria and that were not identified by our search
strategy or that were missed during the screening titles and abstracts
procedure were identified by cross-checking relevant literature. In to-
tal, 176 articles fulfilled the inclusion criteria.
Description of participants
A brief description of participants’ characteristics is provided through-
out the text and/or in the tables.
Description of interventions
In general, sexual function and fertility outcomes were evaluated in a
few studies before and after exposure to immunosuppressive drugs. In
cross-sectional studies, disease activity and co-medication used during
the study were not uniformly reported.
The publications regarding pregnancy and child outcomes were ob-
servational; no standardised interventions were studied.
Risk of bias within studies
Regarding sexual function, reproductive hormones and male fertility,
the overall quality of the included studies was low to moderate and
the number of exposed cases was low for all the drugs included in this
systematic review. Regarding pregnancy outcomes, case series and
small cohorts were of low quality (<5) in general. High scores (5)
were given to the population-based registries from Denmark and
Norway and transplantation registries.
Outcomes
In the upcoming text, we provide a summary of the main outcomes
from the included studies. More in-depth information regarding the
findings and study quality per study is presented in Tables I and II and
in the Supplementary tables. Table I contains information regarding fer-
tility, reproductive hormones and sexual function outcomes. Table II
contains information about pregnancy outcomes, gestational age, birth
weight and birth defects. Supplementary Table S2 contains more study
specifications. Reported specification of the birth defects is presented
in Supplementary Table S3. Other maternal and child outcomes are
reported in Supplementary Table S4.
Paternal exposure was included in this systematic review if paternal
exposure occurred 6 months before conception or around the time of
conception. Some of the included studies also presented results for
exposure at any time before conception. Comparison between ‘expo-
sure 3 months prior to conception’ and ‘exposure at any time before
conception’ was possible in publications of the Danish registry data
(Larsen et al., 2016; Egeberg et al., 2017; Nørgaard and Andersen,
2019). See Supplementary Table S5 for outcomes after exposures any
time before conception. No major changes were found in the risk esti-
mates, only small changes were seen with a very low number of cases.
Aminosalicylic acid and similar agents
Sexual function, reproductive hormones and fertility.
There were 22 studies with data on a total of 329 exposed men to
sulfasalazine identified. Sperm analysis abnormalities were reported in
40–100% of those patients exposed to sulfasalazine (doses ranged
from 2 to 4 mg/day). The most common sperm abnormality reported
was asthenozoospermia (decreased motility) followed by decreased
sperm counts and abnormal morphology. Data extracted from case
reports and small case series showed that oligospermia and astheno-
zoospermia were severe enough to cause male infertility. In all studies
where follow-up samples were available, sperm quality improved after
sulfasalazine was withdrawn for 3 months. The majority of these stud-
ies were published between 1979 and 1987 and included patients diag-
nosed with IBD (Levi et al., 1979; Toth, 1979; Traub et al., 1979;
Birnie et al., 1981; Heineman et al., 1981; Toovey et al., 1981;
Freeman et al., 1982; Hudson et al., 1982; Tobias et al., 1982; Cann
and Holdsworth, 1984; Cosentino et al., 1984; Freixa et al., 1984;
McIntyre and Lennard-Jones, 1984; O’Morain et al., 1984; Ragni et al.,
1984; Shaffer et al., 1984; Iglesias-cortit et al., 1985; Riley et al., 1987;
Chatzinoff et al., 1988; Zelissen et al., 1988; Di Paolo et al., 2001;
Ganatra et al., 2018). Importantly, most of these studies are case
reports and case series.
Pregnancy and child outcomes.
No studies were identified.
Antimalarials (chloroquine and
hydroxychloroquine)
Sexual function, reproductive hormones and fertility.
Four studies that included data from 37 healthy men were identified.
One study reported sperm quality parameters and three studies evalu-
ated the ability of chloroquine to cross the blood-testis barrier (Ette
et al., 1988; Adeeko and Dada, 1994; Hargreaves et al., 1998; Ejebe







































..et al., 2008). As it is the case for other human tissues and fluids, chlo-
roquine can be found on seminal plasma even after long-term with-
drawal. One in vitro study reported that high concentrations of
chloroquine in seminal plasma inhibited sperm motility. No studies
reporting these outcomes were identified for hydroxychloroquine.
Pregnancy and child outcomes.
No studies were identified.
Calcineurin inhibitors (ciclosporine,
sirolimus and tacrolimus)
Sexual function, reproductive hormones and fertility.
Fifteen studies including a total of 263 cases and 229 controls were
identified. All of these cases were receiving sirolimus or ciclosporine
for organ transplantation (mainly kidney transplantation). In all 11 stud-
ies included, sperm quality abnormalities and reproductive hormonal
alterations (low testosterone and high FSH/LH levels) were reported
after sirolimus exposure (Misro et al., 1999; Bererhi et al., 2003;
Fritsche et al., 2004; Kaczmarek et al., 2004; Lee et al., 2005; Tondolo
et al., 2005; Deutsch et al., 2007; Skrzypek and Krause, 2007; Zuber
et al., 2008; Boobes et al., 2010; Sajad Hussain et al., 2015). In addi-
tion, reversible infertility associated with sirolimus was reported in
three studies. One prospective study reported that testosterone levels
increased from baseline levels (pre-transplant) in an undefined number
of patients using everolimus (Kramer et al., 2005). Despite the lack of
reproductive safety information for tacrolimus in humans, in these
studies, patients were switched from sirolimus to tacrolimus and their
sperm quality improved.
Nine post-kidney transplant patients exposed to ciclosporine pro-
vided semen samples and no relevant sperm quality abnormalities
were reported. From this group of patients, partners of three out of
four patients were able to conceive while being exposed to ciclo-
sporine (Haberman et al., 1991; Misro et al., 1999). A prospective
study that included pre- and post-kidney transplantation data of 10
men, reported that hypogonadism was present before initiating
treatment with ciclosporine. After 12 months of ciclosporine expo-
sure, levels of testosterone exceeded pre-transplant levels (Samojlik
et al., 1992). Sexual hormone levels were normal and comparable
amongst 21 ciclosporine- and 16 tacrolimus-exposed renal trans-
plant male patients (Kantarci et al., 2004). Similar results were
reported by others (Peces et al., 1994). Sperm concentration was
Records idenfied through 
database searching
n = 5867 
Full-text arcles excluded,
with reasons n = 193
No drug specific outcomes (n=87)
No original data (n=33)
No reproducve outcomes (n=25)
No male outcomes (n=6)
No full text available (n=18)
Duplicate (n=15)
Cancer treatment (n=2)
Drug not included in protocol (n=6)
Languague other than English (n=1)
Title and abstract screening
n = 4204
Full-text arcles 
assessed for eligibility 
n = 354
Studies included in qualitave 
synthesis 
n = 161












Figure 1. Flow diagram for study selection.































































































inversely correlated to the ciclosporine whole blood levels in one
study (Eid et al., 1996).
Pregnancy and child outcomes.
Six studies were aimed at determining the impact of the use of ciclo-
sporine, tacrolimus or sirolimus on pregnancy and child-related out-
comes. Transplant recipients used these medications often in
combinations with other drugs.
Three case reports/case series and two transplantation registries
found no abnormal outcomes (Moskovitz et al., 1988; Holmgren et al.,
2004; Xu et al., 2009; Ecevit et al., 2012; Moritz et al., 2017; Schopf,
2017). A population-based registry found a higher risk of birth defects al-
though this was not statistically significant (Egeberg et al., 2017). Seven
of the 67 children were diagnosed with a congenital anomaly (CA) after
paternal use of ciclosporine. No details of the CAs were provided.
Colchicine
Sexual function, reproductive hormones and fertility.
Eight studies including a total of 166 cases were identified. Most of
these studies were published before 2000. Colchicine exposure (1–2
mg/day) was associated with low sperm counts and motility in five
studies (Merlin, 1972; Ben-Chetrit et al., 1993; Sarica et al., 1995;
Kirchin et al., 1999; Kaya Aksoy et al., 2019). Abnormal sperm analysis
was reported in 40–58% of patients exposed to colchicine (Sarica
et al., 1995; Kaya Aksoy et al., 2019). One study reported normal
cytogenic sperm analysis in two patients diagnosed with gout and ex-
posed to colchicine (Kastrop et al., 1999), one study reported no sig-
nificant sperm analysis abnormalities in patients previously exposed to
colchicine (Levy and Eliakim, 1977) and finally, one study reported no
significant sperm abnormalities in healthy volunteers exposed to colchi-
cine (Bremner and Paulsen, 1976). A possible adverse effect on sperm
quality associated with disease activity was discussed in the most re-
cent study by Kaya Aksoy et al. (2019).
Pregnancy and child outcomes.
Three older studies from an Israeli hospital followed patients with fa-
milial Mediterranean fever (FMF) treated with colchicine (Levy and
Eliakim, 1977; Ehrenfeld et al., 1986; Ben-Chetrit et al., 2004). Only
one study reported specific data on colchicine and spontaneous abor-
tions (no increased risk) (Ben-Chetrit et al., 2004); the other studies
did not report specific outcomes for colchicine-treated patients.
Cyclophosphamide
Sexual function, reproductive hormones and fertility.
There were 20 studies identified, and most of them included patients
who were exposed to cyclophosphamide (CYC) to treat nephrotic
syndromes associated with glomerulonephritis (73%). Most of these
studies reported fertility outcomes from young adults who were ex-
posed to CYC during their childhood. Unfortunately, the mean age of
these participants was not reported in many studies. From these stud-
ies, a clear negative effect on sperm quality and reproductive hor-
mones, mainly causing low sperm counts and high FSH levels, from
CYC is evident (Fairley et al., 1972; Feng et al., 1972; Kumar et al.,
1972; Penso et al., 1974; Pennisi et al., 1975; Etteldorf et al., 1976;
Kirkland et al., 1976; Hsu et al., 1979; Marina and Barcelo, 1979;
Fukutani et al., 1981; Trompeter et al., 1981; Ogata et al., 1982;
Watson et al., 1985; Perrone et al., 1989; Bogdanovic et al., 1990;
Masala et al., 1997; Anserini et al., 2002; Soares et al., 2007; Suehiro
et al., 2008). Reversibility (improvement in sperm counts after CYC
withdrawal) with a possible dose-dependent effect was a repetitive
finding in some studies. Because of substantial methodological prob-
lems (selection bias, loss of follow-up and no baseline samples), re-
versibility and a dose-dependent effect cannot be interpreted as
conclusive evidence.
Pregnancy and child outcomes.
In 1983, a case report was published noting that a child was born with
an absent hand after paternal exposure to cyclophosphamide and
dexamethasone (Balci and Sarikayalar, 1983).
Interleukin inhibitors
Sexual function, reproductive hormones and fertility.
No studies were identified.
Pregnancy and child outcomes.
Three case series from different sources focused mainly on maternal
exposures and briefly mentioned paternal exposures (Weber-
Schoendorfer and Schaefer, 2016; Youngstein et al., 2017; Warren
et al., 2018). The paternal exposures included two pregnancies where
the male partners were on tocilizumab (one healthy liveborn and one
spontaneous abortion), and 54 pregnancies on where the male part-
ners were on secukinumab (Weber-Schoendorfer and Schaefer,
2016). Outcomes were not available for 20 pregnancies (7 were pend-
ing and 13 were lost to follow-up), while known outcomes were 29
liveborn with one malformation, four spontaneous abortions and one
elective termination (Warren et al., 2018).
Youngstein et al. reported six children with paternal exposure of
anakinra and five children with paternal exposure of canakinumab; no
malformations were reported (Youngstein et al., 2017).
Methotrexate
Sexual function, reproductive hormones and fertility.
Six studies reporting fertility outcomes in patients exposed to metho-
trexate (MTX) were identified. These studies included a total of 47
cases (40 men diagnosed with psoriasis and seven with IMD) and
1912 controls (all controls come from one study (Ley et al., 2018)). In
patients exposed to MTX, sperm concentration decreased in three
studies (Van Scott and Reinertson, 1959; Sussman and Leonard, 1980;
Pandhi et al., 2006), no differences were reported in two studies (one
study reported five normal testicular biopsies after MTX exposure)
(El-Beheiry et al., 1979; Ley et al., 2018) and the sperm quality of one
group of patients diagnosed with psoriasis and exposed to MTX was
better than patients treated with high dose glucocorticoids (Grunnet
et al., 1977).
Pregnancy and child outcomes.
Three case reports from before 2000 reported only healthy liveborn
children (Perry, 1983; Griggs and Schwartz, 2006; Lamboglia et al.,
2009). More recent case series and cohort studies (169 pregnancies
and 193 liveborn children) found no increased risk of birth defects as-
sociated with paternal MTX exposure (Beghin et al., 2011; Engeland
et al., 2013; Weber-schoendorfer et al., 2014; Winter et al., 2017;































































































Drenches et al., 2018). This also applies to the rate of spontaneous
abortions, preterm birth and small for gestational age (SGA; Weber-
schoendorfer et al., 2014; Winter et al., 2017; Andersen et al., 2018).
Friedman et al. used the Danish registries to look at long-term out-
comes and no negative impact of paternal preconception use of MTX
was reported (Friedman et al., 2017).
Mycophenolate acid products
Sexual function, reproductive hormones and fertility.
No studies were identified.
Pregnancy and child outcomes.
Four data sources have published data with 295 pregnancies and 189
children included: three registries, two population-based and one preg-
nancy transplantation with medical records from one hospital in Spain
(Jones et al., 2013; Åsberg et al., 2017; Egeberg et al., 2017; Midtvedt
et al., 2017; Moritz et al., 2017; Lopez-Lopez et al., 2018). No major
differences were found compared to transplantation patients not taking
mycophenolate acid products (MPAs). In these studies, MPA was of-
ten used in combination with calcineurin inhibitors and corticosteroids.
Non-steroidal anti-inflammatory drugs
(NSAIDs)
Sexual function, reproductive hormones and fertility.
For NSAIDs as a group, no studies were identified in our population
of interest. Nonetheless, six studies that included healthy participants
were identified. Exposure to salicylate decreased sperm motility, and
for naproxen one study concluded that sperm quality abnormalities
were similar between pre- and post- exposed samples (Bendvold
et al., 1985; Knuth et al., 1989; Poratsoldin and Soldin, 1992). A study
from Kristensen et al. concluded that ibuprofen exposure results in a
state of compensated hypogonadism (Kristensen et al., 2018). One
in vitro study using adult human testis explants demonstrated that ex-
posure to indomethacin and aspirin altered the production of testos-
terone by Leydig cells (Albert et al., 2013).
Pregnancy and child outcomes.
No studies were identified.
Retinoids (acitretin, etretinate and
isotretinoin)
Sexual function, reproductive hormones and fertility.
Eight studies that included a total of 203 cases and 20 controls were
identified (Torok et al., 1987; Parsch et al., 1990; Coleman and
MacDonald, 1994; Rossi and Pellegrino, 2009; Schmitt-Hoffmann et al.,
2011; Çinar et al., 2016; Liu et al., 2017; Healy et al., 2018). Low con-
centrations of retinoids that are unlikely associated with a teratogenic
risk can be found in seminal plasma of exposed patients (Schmitt-
Hoffmann et al., 2011). No negative effect on sperm quality was
reported in four studies (130 exposed men). Sexual dysfunction in the
form of ejaculatory failure and erectile dysfunction associated with aci-
tretin has been reported (Healy et al., 2018).
Pregnancy and child outcomes.
Three studies report paternal retinoid use and pregnancy-related out-
comes. Two included only liveborn children. A long-term general
follow-up study after etretinate use, with 18 male patients, found three
healthy children (Katugampola and Finlay, 2006). Population-based reg-
istries from Norway found a higher risk (OR (95% CI) 1.8 (0.81–3.8)
for preterm birth (live birth after at least 22 and prior to 37 weeks of
gestation) based on 80 isotretinoin cases (Engeland et al., 2013). Based
on population-based registries, a study from Denmark found no risk
for spontaneous abortion after acitretin use (Nørgaard and Andersen,
2019).
Systemic corticosteroids
Sexual function, reproductive hormones and fertility.
Two studies were identified. In a study from 1956, seven patients diag-
nosed with RA were treated with 75 mg of cortisone over periods
ranging from 23 to 334 days. Pre- and post-treatment testicular biop-
sies were performed for six patients, in which no significant changes
were reported (McDonald and Heckel, 1956). In a small study that in-
cluded 36 men with long standing active RA, the use of prednisone at
doses ranging from 5 to 10 mg/day was associated with significantly
lower testosterone levels and lower levels of FSH and LH compared
to men with long standing RA but without prednisone treatment
(Martens et al., 1994). Because of the scope of our systematic review,
studies that reported the effect of corticosteroids on the male repro-
ductive health of healthy controls were excluded. A review on this
topic can be found elsewhere (Drobnis and Nangia, 2017).
Pregnancy and child outcomes.
A high number of cases were reported in the population-based studies
of Norway and Denmark. Data from Norway refer to prednisolone
(Engeland et al., 2013). No drug-specific information about systemic
corticosteroids in the Danish data was available and both registries
have no information about the used dose or indication. Larsen et al.
only found a higher risk of birth defects in the Danish registries, al-
though it was not statistically significant, after one or two redeemed
prescriptions (Larsen et al., 2018). Smaller numbers are reported in
transplantation patients (Penn et al., 1971; McGeown and Nevin,
1978; Xu et al., 2011).
Thiopurines
Sexual function, reproductive hormones and fertility.
Four studies that included a total of 75 cases and 40 controls exposed
to azathioprine were included (Baumgarten et al., 1977; Farthing and
Dawson, 1983; Dejaco et al., 2001; Grosen et al., 2019c). Sperm qual-
ity, sperm DNA fragmentation index (DFI) and the male endocrine re-
productive axis appear not to be negatively affected by azathioprine
exposure.
Pregnancy and child outcomes.
Azathioprine is the most frequently reported thiopurine followed by 6-
mercaptopurine. The first hospital case series were reported in the
1970s (Penn et al., 1971; McGeown and Nevin, 1978). In the early
2000s, other case series followed and the largest study up to now was
based on the Danish registries from 2017. No differentiation between
the two drugs was made (Rajapakse et al., 2000; Francella et al., 2003;































































































Xu et al., 2009, 2011; Teruel et al., 2010; Hoeltzenbein et al., 2012;
Nørgård et al., 2017). In total 192 males, 211 pregnancies and 669
children were included in these studies. Overall, no increased risks
were detected.
Friedman et al. used the Danish registries to look at long-term out-
comes and no negative impact of paternal preconception use of azathi-
oprine or 6-mercaptopurine was reported (Friedman et al., 2017).
Tumour necrosis factor-a inhibitors
Sexual function, reproductive hormones and fertility.
We identified 15 studies that evaluated the effect of tumour necrosis
factor (TNF)-a inhibitors on male sexual health. Thirteen studies
reported fertility or sperm quality outcomes, one study reported sex-
ual function as an outcome (Oh et al., 2009) and priapism secondary
to the use of adalimumab was reported in one case report
(Kreitenberg et al., 2015). In total, outcomes of interest were reported
in 156 men diagnosed with ankylosing spondylitis (AS), psoriasis, RA
and IBD exposed to TNF-a inhibitors and in 225 men who partici-
pated in these studies as healthy controls.
Regarding sperm quality before and after TNF-a inhibitor use, one
small randomised control trial (RCT) that included data of 20 men
concluded that certolizumab pegol had no adverse event on sperm
quality compared to placebo (Perrier d’Hauterive et al., 2012). In stud-
ies where a comparison between baseline samples before TNF-a in-
hibitor exposure and follow-up samples was available, no differences
on sperm quality were reported in five studies (Almeida et al., 2013;
Micu et al., 2014, 2019; Heppt et al., 2017; Grosen et al., 2019a),
while in three studies sperm quality improved after exposure (Villiger
et al., 2010; Ramonda et al., 2014; Pascarelli et al., 2017) and in one
study sperm quality worsened after exposure (Mahadevan et al.,
2005). A possible positive effect on sperm quality using TNF-a inhibi-
tors could be the result of decreasing disease activity in patients with
AS. These findings should not be extrapolated to other diseases until
more research is available.
One study showed that exposure to TNF-a inhibitors in a group of
men diagnosed with AS resulted in improvement of sexual function
scores (Oh et al., 2009).
Pregnancy and child outcomes.
Eight small studies and one large population-based cohort were identi-
fied (Lamboglia et al., 2009; Paschou et al., 2009; Saougou et al., 2013;
Clowse et al., 2015; Larsen et al., 2016; Hoxha et al., 2017; Uyaroglu
et al., 2017; Lichtenstein et al., 2018; Micu et al., 2019). In total, 61
males, 121 pregnancies and 372 children were included. Overall, no in-
creased risk was found. Larsen found a higher risk for SGA infants
based on 16 cases, although this was not statistically significant.
Verdolizumab
Sexual function, reproductive hormones and fertility.
One study from Denmark that included data on 15 male patients diag-
nosed with IBD with a mean age of 33 years and 40 healthy controls
with a mean age of 23 years was identified. After exposure to verdoli-
zumab, the sperm DFI was similar amongst the two groups (Grosen
et al., 2019b).
Pregnancy and child outcomes.
No studies were identified.
Other selective immunosuppressants
Pregnancy and child outcomes.
All publications contained mostly maternal exposure cases and only
briefly mention paternal exposures. The results for the paternal expo-
sure were one case report on leflunomide reporting a healthy child
(De Santis et al., 2005) and two case series from the industry on aba-
tacept (10 pregnancies) and tofacitinib (84 pregnancies) revealing no
safety concerns (Kumar et al., 2015; Mahadevan et al., 2018).
Immunosuppressive drugs without available
information
For many immunosuppressive drugs, no studies were identified. In
Table III, the most relevant immunosuppressive drugs where no avail-
able data were available are presented.
Treatment of antisperm antibodies
Antisperm antibodies are considered as an important cause of male in-
fertility and often are associated with autoimmunity. Although not in-
cluded in the original scope of our systematic review, we identified a
considerable number of studies regarding the treatment of antisperm
antibodies (mainly associated with male infertility) using glucocorti-
coids. These studies reported mixed results and overall the risks asso-
ciated with glucocorticoid therapy outweighed the benefits. In-depth
information can be found elsewhere (Drobnis and Nangia, 2017).
Discussion
Summary of evidence
Sexual function, reproductive hormones and fertility.
Regarding sexual function, reproductive hormones and fertility, most
of the available information focuses on the effect of immunosuppres-
sive drugs on male fertility (specifically on sperm quality). Less informa-
tion was available for sexual function or reproductive hormones.
Based on the available information on the effect of immunosuppres-
sive drugs on male sexual function, reproductive hormones and fertil-
ity, the following classification is provided.
No negative effect was observed for acitretin, azathioprine, ciclo-
sporine, isotretinoin, TNF-a inhibitors and verdolizumab.
Negative effects were reported for cyclophosphamide, sirolimus and
sulfasalazine.
Unclear effects were noted for chloroquine, colchicine, methotrex-
ate, NSAIDs and systemic glucocorticoids.
Worth mentioning is that TNF-a plays an important role in sperma-
togenesis and testicular homeostasis; one of the main findings for this
group of drugs is that disease activity itself might play a role in baseline
sperm quality characteristics and on the subsequent effect that TNF-a
inhibitors have on sperm quality. At least for patients diagnosed with
AS, TNF-a inhibitors appeared to have a positive effect on sperm
quality. As it is the case for most of the drugs included in this system-
atic review, further research is needed.









































































Disease activity was taken into consideration in the study design of
a few studies. By doing this, authors showed that disease activity can
also induce sperm abnormalities (Villiger et al., 2010; Ganatra et al.,
2018; Kaya Aksoy et al., 2019). Considering that IMDs have different
inflammatory phenotypes, the effect of disease activity could be an im-
portant confounder in future studies on the impact of medications on
sperm quality.
Pregnancy and child outcomes.
Regarding pregnancy and child outcomes, we found no clear evidence
to support restriction in the prescription of these drugs. Although the
number of patients was low in case reports and series, and in small
cohorts, in some cases, detailed information is available. In contrast, in
population-based registries, predominantly from Denmark, larger num-
bers of patients have been reported. In these populations, odds ratios
or hazard ratios can be calculated but they lack important detailed in-
formation about the dose, indication and co-medication.
Findings
Sexual function, reproductive hormones and fertility.
The effects of many immunosuppressive drugs on sexual function, re-
productive hormones and fertility have not been properly evaluated.
Many factors can contribute to this situation, for example, sperm sam-
ples are needed to evaluate sperm quality and this may lead to many
logistic problems. In addition, there is a general misconception that
male contributions to pregnancy are not important, which can contrib-
ute to a lack of interest by researchers and clinicians.
Furthermore, the effect of immunosuppressive drugs on sexual func-
tion, reproductive hormones and fertility cannot be studied separately.
Multiple factors are interconnected in this process and should be con-
sidered in clinical practice and in future research.
Pregnancy and child outcomes.
The possible influence of paternal exposure before conception on
pregnancy and child outcomes is also a neglected topic. In the last
years, the number of publications has been increasing. In most cases,
these studies include maternal and paternal exposures with little atten-
tion to the outcomes secondary to paternal exposure. Most of the
time, no in-depth details of the paternal cases were available.
Strengths and limitations
The strengths of this study are based on the design and conduction of
the systematic review. It followed strict pre-specified and reproducible
methods. A comprehensive search strategy was developed to summa-
rise the available information on many aspects of sexual health and re-
production. We did not restrict the search to a specific disease or
drug (group) but tried to compile information about all important
drugs (groups) used for several IMDs. Systematic reviews can also
demonstrate where knowledge is lacking, and we consider that this is
another major strength of this review. Major areas of opportunities for
future research regarding this topic were identified.
Unfortunately, several limitations should be addressed. Most of the
studies included small numbers of patients and controls. In addition,
studies about sexual function, reproductive hormones and fertility in
men with IMDs suffer from an inconsistent methodological quality; dis-
ease activity was not evaluated as a potential confounder in many
studies; relevant comorbidities that also have a direct effect on these
outcomes were not reported in all studies. Results might only apply to
the specific populations studied.
Importantly, our findings should be interpreted with caution since a
significant proportion of our included studies are case reports and
small case series that tend to overestimate the outcomes of interest.
Regarding the pregnancy and child outcomes, the level of detail and
specific information that is available in the publications needs to
improve.
In this review, no animal studies were included. Animal studies
show effects on reproductive outcomes for drugs such as methotrex-
ate and thiopurines (Grosen et al., 2017; Simsek et al., 2018).
Outcomes of animal studies are not always predictive for humans.
Based on these outcomes and in addition to the lack of well-
documented human paternal exposures in large studies, a restrictive
wording is placed in the summary of product characteristics by the
regulatory agencies.
Research recommendations
For many immunosuppressive drugs that are prescribed to millions of
men with IMD, such as methotrexate or hydroxychloroquine, the pos-
sibility of re-evaluating their reproductive toxicity is of major impor-
tance and should be discussed. Semen analysis is still considered to be
the most valid method to evaluate testicular toxicity in humans.
............................................................................................................................................................................................................................
Table III Immunosuppressive drugs included in the search strategy without studies included in the final data analysis.
Sexual function, reproductive hormones and fertility Pregnancy outcomes
Anakinra JAK inhibitors Apremilast JAK inhibitors
Apremilast Leflunomide Belimumab NSAIDs
Belimumab Rituximab Canakinumab Rituximab
Canakinumab Ruxolitinib COX 2 inhibitors Ruxolitinib
Human immunoglobulin Secukinumab Everolimus Sulfasalazine
Hydroxychloroquine Tacrolimus Human immunoglobulin Tioguanine
Ixekizumab Tocilizumab Ixekizumab Tocilizumab



























































Ideally, RCTs and case–control well-designed prospective cohort stud-
ies should be designed to reach conclusive evidence.
While experimental studies are not ethical for assessing reproduc-
tive toxicity, observational studies such as those utilising case–control
or cohort designs may be and should be considered. As a rule of
thumb, if no increased incidence of malformations is observed within
at least 1000 prospectively collected pregnancies, a conclusion might
be reached that the drug of interest is not responsible for a 2-fold or
more increase of the overall incidence of malformations (EMA, 2008).
Several factors such as the number of exposed patients, the inci-
dence of the outcome in the unexposed control group, the minimum
relative risk to be detected and the ratio of unexposed control to ex-
posed study subjects can affect the power of a cohort study and
should be considered during the early stages of a study design (Strom,
2020).
Focusing only on the prevalence of exposure and in order to put this
into perspective, for frequently used drugs (>10% of the population),
such as paracetamol, smaller sample sizes are needed to detect an in-
creased risk of congenital malformations. For such drugs, the required
sample size ranges from 8140 participants in a population cohort
study to 614 participants in a case–control study. This range increases
drastically for less frequently used drugs such as rituximab (<1% of the
population), where 814 000 participants are needed in population co-
hort studies to 51 116 participants in case–control studies.
Based on these recommendations and following the example of the
large Scandinavian cohorts here presented, collecting prospective data
on current paternal exposures should be strongly recommended and
considered for future research on this topic. In the meantime, health
care professionals should think about these potential adverse events
and intervene appropriately (see Table IV for research recommenda-
tions for standardisation).
Recently, it has been shown that disease activity can also impair
fertility in men with rheumatic diseases (Villiger et al., 2010; Ganatra
et al., 2018; Kaya Aksoy et al., 2019; Perez-Garcia et al., 2020). In
consequence, it is very important to start focusing on developing
well-designed epidemiological studies where study design and data
analysis consider how diseases and drugs together can affect sexual
health and reproduction.
To improve the overall quality of research on this topic, a call to ac-
tion initiative that gets scientists from many different fields involved in
the topic is needed. This could result in an organised plan to study
and report future research.
Furthermore, access to information is more important than ever
since effective communication has become an essential part of the
treatment shared decision process between health care professionals
and patients. Therefore, discussing the possible effect(s) of immuno-
suppressive drugs on male sexual health and reproduction should be
considered for every man, irrespective of whether they have a wish to
become a father or not.
Conclusion
There is little scientific evidence regarding the potential adverse events
on male sexual function, reproductive hormones and fertility of many
of the commonly used immunosuppressive drugs. Most of the included
studies are heterogeneous and cannot be generalised to a wider popu-
lation. With a lack of conclusive evidence, it is expected that clinicians
and patients are confronted with difficult treatment decisions.
The results of this systematic review did not reveal major safety
issues concerning paternal exposure to immunosuppressive drugs.
However, we have to keep in mind that the numbers are low and an
increased risk cannot be excluded. Well-designed and fully powered
observational cohort studies with longitudinal data should be con-
ducted to properly label these drugs. In cases where the number of
patients included in a study is considered to be too low to reach
Table IV Research recommendations to conduct future research on these topics.
Sexual function Use standardised screening questionnaires (IIEF).
Case–control studies and well-designed prospective cohort studies are encouraged over cross-sectional studies.
Consider relevant comorbidities and potential confounders e.g. depression, anxiety and disease activity.
Sperm quality Use standardised methods to report sperm quality (WHO) (primary endpoint).
DNA fragmentation index could provide more information regarding male fertility potential and should be consid-
ered as a secondary endpoint.
Ideally, technicians should be blinded regarding the drug exposure.
RCTs are ideal but case–control and well-designed prospective cohort studies are also encouraged over cross-
sectional studies.
Consider disease activity, relevant co-medication, comorbidities and potential confounders e.g. age, smoking and
varicocele.
Reproductive hormones Use standardised methods to measure hormones.
RCTs are ideal but case–control and well-designed prospective cohort studies are also encouraged over cross-
sectional studies.
Consider disease activity, relevant comorbidities and potential confounders (age and co-medication)
Pregnancy and offspring outcomes Collect data prospectively or report cases with all the relevant information, e.g. source of the information, indica-
tion, disease activity, clear description of medication use and timing (including co-medication) and paternal age.
Regarding pregnancy/child outcomes, pregnancy outcome, gestational age, birth weight, infant health, genetic test-
ing and follow-up period should be reported.
The partner’s relevant medical history should be considered.































































































adequate power, researchers should use standardised methods to
measure outcomes of interest, ensure the quality of the collected vari-
ables and report their findings according to the STROBE statement
(Vandenbroucke et al., 2007; von Elm et al., 2008). This will provide
the scientific community with valuable information and allow it to per-
form meta-analyses in the future.
In cases of men with a wish to become a father, the sometimes
very restrictive wording in the summary of product characteristics
might not be necessary. In the meantime, in case the patient wishes to
become a father, clinicians must discuss the pros and cons of stopping
or changing drug treatment. The potential negative effects of the dis-
ease on reproductive outcomes and potential flares need to be weight
against theoretical concerns of the drug effects.
Supplementary data
Supplementary data are available at Human Reproduction Update
online.
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Ecevit C, Ünal F, Baran M, Aydogdu S. Parenthood in pediatric liver
transplant patients. Pediatr Transplant 2012;16:346–349.
Eck LK, Jensen TB, Mastrogiannis D, Torp-Pedersen A, Askaa B,
Nielsen TK, Poulsen HE, Jimenez-Solem E, Andersen JT. Risk of ad-
verse pregnancy outcome after paternal exposure to methotrexate
within 90 days before pregnancy. Obstet Gynecol 2017;129:707-714.
Egeberg A, Gislason GH, Nast A. Birth outcomes in children fathered
by men treated with immunosuppressant drugs before concep-
tion—a Danish population-based cohort study. J Invest Dermatol
2017;137:1790–1792.
Ehrenfeld M, Levy M, Margalioth EJ, Eliakim M. The effects of long-
term colchicine therapy on male fertility in patients with familial
Mediterranean fever. Andrologia 1986;18:420–426.
Eid MM, Abdel-Hamid IA, Sobh MA, el-Saied MA. Assessment of
sperm motion characteristics in infertile renal transplant recipients
using computerized analysis. Int J Androl 1996;19:338–344.
Ejebe DE, Ojieh AE, Ovuakporaye SI, Odion-Obomhense HK,
Adegor EC, Amadi CN, Nwadito C, Emudainohwo JOT, Ozoko
TC. Effects of anti-malarial alkaloids on the sperm properties and
blood levels of reproductive hormones of adult men. Afr J
Biotechnol 2008;7:3395–3400.
El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fer-
tility in men. Arch Androl 1979;3:177–179.
EMA. Guideline on Risk Assessment of Medicinal Products on Human
Reproduction and Lactation: From Data to Labelling. European
Medicines Agency, 2008, 1–18. https://www.ema.europa.eu/en/
risk-assessment-medicinal-products-human-reproduction-lactation-
data-labelling.
EMA. ICH S5 (R3) Guideline on Reproductive Toxicology: Detection of
Toxicity to Reproduction for Medicinal Products including Toxicity to
Male Fertility. European Medicines Agency, 2017. https://www.
ema.europa.eu/en/ich-s5-r3-guideline-reproductive-toxicology-de
tection-toxicity-reproduction-human-pharmaceuticals.
Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE,
Furu K. Effects of preconceptional paternal drug exposure on birth
outcomes: cohort study of 340000 pregnancies using Norwegian
population-based databases. Br J Clin Pharmacol 2013;75:
1134–1141.
Ette EI, Ogonor JI, Essien EE. Passage of chloroquine into semen. Br J
Clin Pharmacol 1988;26:179–182.
Etteldorf JN, West CD, Pitcock JA, Williams DL. Gonadal function,
testicular histology, and meiosis following cyclophosphamide ther-
apy in patients with nephrotic syndrome. J Pediatr 1976;88:
206–212.
Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy re-
lated to cyclophosphamide therapy. Lancet 1972;1:568–569.
Farthing MJG, Dawson AM. Impaired semen quality in Crohn’s dis-
ease - drugs, ill health, or undernutrition? Scand J Gastroenterol
1983;18:57–60.
FDA. Testicular Toxicity: Evaluation during Drug Development Guidance




Feng PH, George CR, Evans RA, Murkin GE, Spicer E, Thomas BS,
Hellmann K, Hassib H, Hassib F. Cyclophosphamide and infertility.
Lancet 1972;1:840–842.






























































































..Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH.
The safety of 6-mercaptopurine for childbearing patients with in-
flammatory bowel disease: a retrospective cohort study.
Gastroenterology 2003;124:9–17.
Freeman JG, Reece VAC, Venables CW. Sulphasalazine and sperma-
togenesis. Digestion 1982;23:68–71.
Freixa R, Rosello Catafau J, Gelpi E. Comparative study of antiinflam-
matory drugs and sulphasalazine in relation to prostaglandin E and
19 hydroxylated prostaglandin E levels and human male fertility.
Prostaglandins Leukot Med 1984;16:359–369.
Friedman S, Larsen MD, Magnussen B, Jølving LR, de Silva P,
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Lamboglia F, D’Incà R, Oliva L, Bertomoro P, Sturniolo GC. Patient
with severe Crohn’s disease became a father while on methotrex-
ate and infliximab therapy. Inflamm Bowel Dis 2009;15:648–649.
Larsen MD, Friedman S, Magnussen B, Nørgård BM. Birth outcomes
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